1-2 of 2
Marc Broudy
Close
Sort by
Journal Articles

Potent Antitumor Activity of AP24534, an Orally Active Inhibitor of Bcr-Abl Variants Including T315I, in In Vitro and In Vivo Models of Chronic Myeloid Leukemia (CML).

Victor M. Rivera, PhD, Qihong Xu, PhD, Frank Wang, PhD, Joseph Snodgrass, PhD, Thomas O’Hare, PhD, Amie S. Corbin, Jeffrey Keats, Sarah Lamore, Yaoyu Ning, Scott Wardwell, Karin Russian, Marc Broudy, William C. Shakespeare, PhD, Brian J. Druker, MD, John D. Iuliucci, PhD, Tim Clackson, PhD
Journal: Blood
Blood (2007) 110 (11): 1032.
https://doi.org/10.1182/blood.V110.11.1032.1032
Published: 2007
Journal Articles

Orally Active Inhibitors of the Imatinib Resistant Bcr-Abl Mutant T315I.

William C. Shakespeare, PhD, Frank Wang, Ph.D., Qihong Xu, Ph.D., Xiaotian Zhu, Ph.D., Narayana Narasimham, Ph.D., Chester A. Metcalf, Ph.D., Yihan Wang, Ph.D., Raji Sundaramoorthi, Ph.D., Wei-Sheng Huang, Ph.D., Dong Zou, Ph.D., Mathew Thomas, Ph.D., Jan Romero, Ph.D., David Wen, M.S., Ingrid Chen, B.S., Lisi Cai, M.S., Shuangying Liu, M.S., Scott Wardwell, B.S., Yaoyu Ning, M.S., Jeff Keats, B.S., Joseph Snodgrass, Ph.D., Karin Russian, M.S., Marc Broudy, B.S., Thomas O’Hare, Ph.D., Caitlyn Smith, B.S., Amie Corbin, Ph.D., Brian Druker, M.D., John Iuliucci, Ph.D., David Dalgarno, Ph.D., Tomi K. Sawyer, Ph.D., Tim Clackson, Ph.D.
Journal: Blood
Blood (2006) 108 (11): 2180.
https://doi.org/10.1182/blood.V108.11.2180.2180
Published: 2006